Pine Pharmaceuticals LLC

Pine Pharmaceuticals LLC, an FDA-registered 503B outsourcing facility headquartered in Tonawanda, New York, manufactures metabolic stable isotopes, compounded pharmaceuticals, and specialized research compounds for federal biomedical and clinical research programs as a small-business prime contractor. The company operates across 100% prime awards (45 total) without subcontract relationships, competing predominantly under total small business set-asides on purchases and firm fixed-price delivery orders under indefinite delivery contracts with the National Institutes of Health and the Department of Veterans Affairs.

Pine's customer base is heavily concentrated in HHS biomedical research. The National Institute of Diabetes and Digestive and Kidney Diseases dominates both volume and dollars, representing 21 of 45 awards (47% of award count) worth $9 million combined potential value (88% of total portfolio value). The source describes Pine as holding a $7.27 million single-award indefinite delivery contract with NIDDK for metabolic isotopes running through September 29, 2029, designated as a total small business set-aside, from which multiple delivery orders have been issued. The Veterans Integrated Service Network 23 (Department of Veterans Affairs) is the second customer by both count and value, with 4 awards worth $233 thousand for 503B pharmaceutical compounding services under a $136,915 single-award indefinite delivery contract running through March 31, 2026. The National Cancer Institute, National Heart Lung and Blood Institute, National Institute on Drug Abuse, and National Human Genome Research Institute round out active HHS relationships, accounting for the remaining 26% of awards.

Pine's capability portfolio centers on manufacturing intravenous stable isotopes (6,6 deuterated glucose, D5 glycerol, deuterium oxide) and oral stable isotope formulations to support metabolic research tracing glucose and substrate metabolism in human clinical studies. Representative recent work includes a $410,843 delivery order from NIDDK issued July 8, 2026, for deuterium oxide (70%), D5 glycerol, and 6,6 deuterated glucose under a total small business set-aside; a $69,466 August 14, 2025 delivery order from NIDDK for intravenous stable isotope glucose to support metabolic research; a $125,813 September 16, 2024 purchase order from NIDDK awarded on a sole-source basis for 6,6 deuterated glucose and D5 glycerol; and a $237,923 June 30, 2023 purchase order from NIDDK for intravenous stable isotopes. Pine also delivers 503B compounding pharmaceutical services including placebo capsule manufacturing and compounding of investigational drug dilutions for VA medical programs and NIH drug-development studies—illustrated by a $21,673 October 1, 2025 delivery order from VA VISN 23 for 503B compounding pharmaceuticals, and a $23,754 December 14, 2021 purchase order from the National Center for Advancing Translational Sciences for compounding of polysorbate-80 to dilute an investigational drug for peritoneal cancer treatment.

The primary parent vehicles are two indefinite delivery contracts: the NIDDK metabolic isotopes IDC (8 task orders, $922 thousand combined potential value) and a second IDC (3 task orders, $97 thousand combined potential value). Award trajectory shows variability—4 awards in 2022, 5 in 2023, 8 in 2024, 6 in 2025, and 2 through July 2026—with only 2 awards worth $450 thousand reaching ultimate completion within the next 24 months, creating minimal near-term recompete exposure. The company's federal portfolio reflects over 37 years of operational history serving federal biomedical research agencies, with 27% of combined potential value obligated across the 45-award set ($2.8 million obligated of $10.2 million potential).